https://www.multivu.com/axsome_therapeutics/9389351-en-fda-approval-auvelity-alzheimers-agitation
Axsome Therapeutics Announces FDA Approval of AUVELITY® (dextromethorphan HBr and bupropion HCl)...
AUVELITY is a first-in-class treatment, which targets the NMDA and sigma-1 receptors, approved for agitation associated with dementia due to Alzheimer’s disease
therapeutics announcesfda approvalaxsomehbrbupropion
https://www.axsome.com/science/medical-information/
Medical Information for U.S. Residents - Axsome Therapeutics
Dec 2, 2024 - Learn how patients, caregivers, or HCPs in the U.S. can report suspected adverse events or submit questions. Fill out a form to request medical information or...
medical informationresidentsaxsometherapeutics
https://www.ibtimes.com.au/axsome-therapeutics-stock-surges-138-23193-fda-approval-strong-q1-results-1868165
Axsome Therapeutics Stock Surges 13.8% to $231.93 on FDA Approval and Strong Q1 Results
May 5, 2026 - NEW YORK — Axsome Therapeutics Inc. shares jumped more than 13.8 percent to $231.93 in early trading Monday, May 4, 2026, extending gains after the company...
stock surgesfda approvalaxsometherapeuticsstrong
https://www.axsome.com/conditions/
CNS Conditions - Axsome Therapeutics
Nov 29, 2024 - Learn more about the conditions we focus on and the work Axsome is doing to bring meaningful changes for patients with CNS conditions.
cnsconditionsaxsometherapeutics
https://www.axsome.com/about-axsome/
About Axsome - Axsome Therapeutics
Jan 26, 2025 - See how Axsome is transforming the CNS treatment approach by developing therapeutic options that improve patients’ lives in a meaningful way.
axsometherapeutics
https://www.axsome.com/about-axsome/management-team/
Management Team - Axsome Therapeutics
Dec 3, 2024 - Meet our passionate and patient-focused management team.
management teamaxsometherapeutics
https://www.axsome.com/conditions/depression/
Depression - Axsome Therapeutics
Jan 26, 2025 - What is Major Depressive Disorder? Major Depressive Disorder (MDD) is a serious, biologically-based disorder: It is prevalent and debilitating, and can be...
depressionaxsometherapeutics
https://www.axsome.com/about-axsome/state-disclosures/
State Disclosures - Axsome Therapeutics
Jan 25, 2025 - View state-specific disclosures for California, Colorado, and Vermont.
statedisclosuresaxsometherapeutics
https://www.axsome.com/privacy-notice/
Privacy Notice - Axsome Therapeutics
Nov 29, 2024 - (Effective: December 23, 2022) In this Privacy Policy (“Policy”), we describe how Axsome Therapeutics, Inc. and our affiliates and subsidiaries (“Axsome,” the...
privacy noticeaxsometherapeutics
https://www.axsome.com/conditions/excessive-daytime-sleepiness/
Excessive Daytime Sleepiness - Axsome Therapeutics
Jan 26, 2025 - Excessive daytime sleepiness (EDS) is one of the most common symptoms of obstructive sleep apnea (OSA) and narcolepsy. See key facts about EDS and learn more...
excessivedaytimesleepinessaxsometherapeutics
https://www.axsome.com/conditions/narcolepsy/
Narcolepsy - Axsome Therapeutics
Jan 26, 2025 - Narcolepsy is a serious and debilitating neurological condition. Learn about Axsome's work in narcolepsy, key facts and the unmet needs of patients.
narcolepsyaxsometherapeutics
https://axsomehcpsamples.qpharmacorp.com/
Axsome Therapeutics
axsometherapeutics
https://www.axsome.com/terms-of-use/
Terms of Use - Axsome Therapeutics
Apr 21, 2025 - (Effective: March 15, 2021) Axsome Therapeutics, Inc. and its affiliates (together, “Axsome” or “we”) welcome you to our web sites (“Site(s)”) to learn more...
termsuseaxsometherapeutics
https://axsomemedicalaffairs.com/
Homepage - Axsome Medical Affairs
Jun 30, 2025 - Welcome to Axsome US Medical Affairs Axsome Therapeutics, Inc. is a biopharmaceutical company developing novel therapies for central nervous system (CNS)...
homepageaxsomemedicalaffairs
https://www.axsome.com/
Homepage - Axsome Therapeutics
Jan 31, 2025 - We are committed to developing products that meaningfully improve the lives of patients. Axsome is developing innovative treatments including AXS-05, AXS-12,...
homepageaxsometherapeutics
https://www.axsome.com/conditions/fibromyalgia/
Fibromyalgia - Axsome Therapeutics
Jan 26, 2025 - Approximately 5 million Americans are estimated to suffer from fibromyalgia. Learn about Axsome's work in fibromyalgia and the unmet needs of patients.
fibromyalgiaaxsometherapeutics
https://www.axsome.com/axs-portfolio/pipeline/about-axs-12/
AXS-12 - Axsome Therapeutics
Nov 29, 2024 - AXS-12 (reboxetine) is a norepinephrine reuptake inhibitor being developed for the treatment of narcolepsy. See clinical and regulatory information.
axstherapeutics
https://www.axsome.com/careers/current-opportunities/
Current Career Opportunities - Axsome Therapeutics
Jan 24, 2025 - View a list of current career opportunities at Axsome Therapeutics and submit an application.
current career opportunitiesaxsometherapeutics
https://www.axsome.com/about-axsome/intellectual-property/
Intellectual Property - Axsome Therapeutics
May 7, 2025 - View our broad portfolio of intellectual property, tailored to meet the needs of patients.
intellectual propertyaxsometherapeutics
https://www.axsome.com/conditions/migraine/
Migraine - Axsome Therapeutics
Apr 9, 2025 - Migraine is common and debilitating, affecting over 37 million Americans. Learn about Axsome's work in migraine, key facts and the unmet needs of patients.
migraineaxsometherapeutics
https://www.axsome.com/science/publications/
Publications - Axsome Therapeutics
Jan 27, 2025 - View scientific publications from Axsome.
publicationsaxsometherapeutics
https://www.pharmafocusamerica.com/news/axsome-therapeutics-projects-8-billion-peak-sales-for-auvelity-following-fda-expansion-to-alzheimers-agitation
Axsome Therapeutics Projects $8 Billion Peak Sales for Auvelity Following FDA Expansion to...
Axsome Therapeutics anticipates peak sales of $8 billion for its Auvelity drug after securing FDA approval for treating agitation in Alzheimer's disease.
axsometherapeuticsprojectsbillionpeak